Suppr超能文献

联合骨髓和肾脏移植诱导特异性耐受

Combined Bone Marrow and Kidney Transplantation for the Induction of Specific Tolerance.

作者信息

Chen Yi-Bin, Kawai Tatsuo, Spitzer Thomas R

机构信息

Bone Marrow Transplant Unit, Department of Medicine, Massachusetts General Hospital, Boston, MA 02114, USA.

Transplantation Unit, Department of Surgery, Massachusetts General Hospital, Boston, MA 02114, USA.

出版信息

Adv Hematol. 2016;2016:6471901. doi: 10.1155/2016/6471901. Epub 2016 Apr 30.

Abstract

The induction of specific tolerance, in order to avoid the detrimental effects of lifelong systemic immunosuppressive therapy after organ transplantation, has been considered the "Holy Grail" of transplantation. Experimentally, tolerance has been achieved through clonal deletion, through costimulatory blockade, through the induction or infusion of regulatory T-cells, and through the establishment of hematopoietic chimerism following donor bone marrow transplantation. The focus of this review is how tolerance has been achieved following combined bone marrow and kidney transplantation. Preclinical models of combined bone marrow and kidney transplantation have shown that tolerance can be achieved through either transient or sustained hematopoietic chimerism. Combined transplants for patients with multiple myeloma have shown that organ tolerance and prolonged disease remissions can be accomplished with such an approach. Similarly, multiple clinical strategies for achieving tolerance in patients without an underlying malignancy have been described, in the context of either transient or durable mixed chimerism or sustained full donor hematopoiesis. To expand the chimerism approach to deceased donor transplants, a delayed tolerance approach, which will involve organ transplantation with conventional immunosuppression followed months later by bone marrow transplantation, has been successful in a primate model. As combined bone marrow and organ transplantation become safer and increasingly successful, the achievement of specific tolerance may become more widely applicable.

摘要

为避免器官移植后终身系统性免疫抑制治疗的有害影响,诱导特异性耐受被视为移植领域的“圣杯”。在实验中,通过克隆清除、共刺激阻断、诱导或输注调节性T细胞以及在供体骨髓移植后建立造血嵌合体等方式实现了耐受。本综述的重点是在联合骨髓和肾脏移植后如何实现耐受。联合骨髓和肾脏移植的临床前模型表明,通过短暂或持续的造血嵌合体可以实现耐受。针对多发性骨髓瘤患者的联合移植表明,采用这种方法可以实现器官耐受并延长疾病缓解期。同样,在短暂或持久的混合嵌合体或持续完全供体造血的背景下,也描述了多种在无潜在恶性肿瘤患者中实现耐受的临床策略。为了将嵌合体方法扩展到已故供体移植,一种延迟耐受方法,即先进行常规免疫抑制的器官移植,数月后再进行骨髓移植,已在灵长类动物模型中取得成功。随着联合骨髓和器官移植变得更安全且越来越成功,特异性耐受的实现可能会得到更广泛的应用。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3bf6/4867066/bbae1441ad93/AH2016-6471901.001.jpg

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验